Global Primary Sclerosing Cholangitis Market Size Study & Forecast, by Type (Classic PSC, Small-Duct PSC, PSC Associated with Autoimmune Hepatitis) by Treatment Type, Symptom Control, and End User, and Regional Forecasts 2025-2035

Description

The Global Primary Sclerosing Cholangitis (PSC) Market is valued at approximately USD 0.33 billion in 2024 and is anticipated to grow at a CAGR of 7.70% over the forecast period 2025-2035. PSC is a rare, chronic liver disorder characterized by progressive inflammation and fibrosis of the bile ducts, eventually leading to liver cirrhosis and failure. Management of PSC involves a combination of therapeutic interventions, symptom control, and monitoring, with treatments targeting disease progression and associated complications. The market is driven by increasing awareness of rare liver diseases, advancements in pharmacological treatments such as ursodeoxycholic acid and obeticholic acid, and rising global healthcare expenditure. Moreover, the growing prevalence of autoimmune disorders and the expansion of specialized liver care centers contribute to market growth.

Rising prevalence of PSC globally, combined with an enhanced focus on early diagnosis and innovative treatment strategies, has significantly propelled the demand for effective therapies. According to recent epidemiological studies, the incidence of PSC varies between 0.5 to 1.3 per 100,000 person-years, with higher rates observed in North America and Europe. The surge in autoimmune hepatitis-associated PSC cases and the development of targeted therapeutics create lucrative avenues for pharmaceutical companies. However, challenges such as limited treatment options, high therapy costs, and the complexity of clinical management may restrain growth during the forecast period.

The detailed segments and sub-segments included in the report are:

By Type:

Classic PSC
Small-Duct PSC
PSC Associated with Autoimmune Hepatitis

By Treatment Type:

Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others

By Symptom Control:

Antihistamines
Cholestyramine
Antibacterials
Opioid Antagonists
Colestipol
Others

By End User:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America

U.S.
Canada

Europe

UK
Germany
France
Spain
Italy
ROE

Asia Pacific

China
India
Japan
Australia
South Korea
RoAPAC

Latin America

Brazil
Mexico

Middle East & Africa

UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Classic PSC Segment Expected to Dominate the Market

Classic PSC represents the largest segment by type, owing to its higher prevalence and well-established clinical recognition among hepatologists. The segment's dominance is driven by the substantial patient base requiring long-term management and monitoring, as well as the availability of clinical protocols for treatment. Increasing research focus on disease-modifying agents and rising awareness campaigns are further consolidating its leading position.

Ursodeoxycholic Acid Leads in Revenue Contribution

Currently, ursodeoxycholic acid-based therapies generate the largest revenue, attributed to their widespread clinical adoption as first-line treatment for slowing disease progression and improving liver function. These therapies benefit from well-documented efficacy, extensive clinical trials, and their ability to address both symptomatic relief and biochemical improvement, making them the primary revenue driver within the treatment type segment.

The Global Primary Sclerosing Cholangitis Market is regionally diverse, with North America leading in market share due to advanced healthcare infrastructure, high disease awareness, and concentrated research activities. Europe maintains a strong position supported by reimbursement policies and robust hepatology networks. Asia Pacific is expected to emerge as the fastest-growing region, driven by increasing diagnosis rates, rising healthcare expenditure, and growing access to specialty liver care facilities. Latin America and the Middle East & Africa are experiencing gradual uptake due to enhanced disease awareness and expanding pharmacy networks.

Major market players included in this report are:

Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Novartis AG
Pfizer Inc.
Takeda Pharmaceutical Company Limited
Roche Holding AG
Sanofi S.A.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Amgen Inc.
Ipsen Pharma
Mitsubishi Tanabe Pharma Corporation
AstraZeneca PLC

Global Primary Sclerosing Cholangitis Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent to up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments and countries in recent years and to forecast the values for the coming years. The report incorporates both qualitative and quantitative aspects of the industry, offering comprehensive insights into growth drivers, challenges, and potential opportunities. Additionally, it presents a detailed competitive landscape, key strategies employed by market leaders, and emerging micro-market opportunities for investment.

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of the geographical landscape with country-level insights.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of the competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Primary Sclerosing Cholangitis Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. key Findings

Chapter 3. Global Primary Sclerosing Cholangitis Market Forces Analysis

3.1. Market Forces Shaping The Global Primary Sclerosing Cholangitis Market (2024-2035)
3.2. Drivers
- 3.2.1. increasing awareness of rare liver diseases
- 3.2.2. advancements in pharmacological treatments
3.3. Restraints
- 3.3.1. limited treatment options and high therapy costs
3.4. Opportunities
- 3.4.1. rising global healthcare expenditure

Chapter 4. Global Primary Sclerosing Cholangitis Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Primary Sclerosing Cholangitis Market Size & Forecasts by Type 2025-2035

5.1. Market Overview
5.2. Global Primary Sclerosing Cholangitis Market Performance - Potential Analysis (2025)
5.3. Classic PSC
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. Small-Duct PSC
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035
5.5. PSC Associated with Autoimmune Hepatitis
- 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.5.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Primary Sclerosing Cholangitis Market Size & Forecasts by Treatment Type 2025-2035

6.1. Market Overview
6.2. Global Primary Sclerosing Cholangitis Market Performance - Potential Analysis (2025)
6.3. Ursodeoxycholic Acid
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Obeticholic Acid
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
6.5. Methotrexate
- 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.5.2. Market size analysis, by region, 2025-2035
6.6. Corticosteroids
- 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.6.2. Market size analysis, by region, 2025-2035
6.7. Others
- 6.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.7.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Primary Sclerosing Cholangitis Market Size & Forecasts by Symptom Control 2025-2035

7.1. Market Overview
7.2. Global Primary Sclerosing Cholangitis Market Performance - Potential Analysis (2025)
7.3. Antihistamines
- 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.3.2. Market size analysis, by region, 2025-2035
7.4. Cholestyramine
- 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.4.2. Market size analysis, by region, 2025-2035
7.5. Antibacterials
- 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.5.2. Market size analysis, by region, 2025-2035
7.6. Opioid Antagonists
- 7.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.6.2. Market size analysis, by region, 2025-2035
7.7. Colestipol
- 7.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.7.2. Market size analysis, by region, 2025-2035
7.8. Others
- 7.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.8.2. Market size analysis, by region, 2025-2035

Chapter 8. Global Primary Sclerosing Cholangitis Market Size & Forecasts by End User 2025-2035

8.1. Market Overview
8.2. Global Primary Sclerosing Cholangitis Market Performance - Potential Analysis (2025)
8.3. Hospital Pharmacies
- 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.3.2. Market size analysis, by region, 2025-2035
8.4. Retail Pharmacies
- 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.4.2. Market size analysis, by region, 2025-2035
8.5. Online Pharmacies
- 8.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.5.2. Market size analysis, by region, 2025-2035

Chapter 9. Global Primary Sclerosing Cholangitis Market Size & Forecasts by Region 2025-2035

9.1. Growth Primary Sclerosing Cholangitis Market, Regional Market Snapshot
9.2. Top Leading & Emerging Countries
9.3. North America Primary Sclerosing Cholangitis Market
- 9.3.1. U.S. Primary Sclerosing Cholangitis Market
  - 9.3.1.1. Type breakdown size & forecasts, 2025-2035
  - 9.3.1.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.3.1.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.3.1.4. End User breakdown size & forecasts, 2025-2035
- 9.3.2. Canada Primary Sclerosing Cholangitis Market
  - 9.3.2.1. Type breakdown size & forecasts, 2025-2035
  - 9.3.2.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.3.2.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.3.2.4. End User breakdown size & forecasts, 2025-2035
9.4. Europe Primary Sclerosing Cholangitis Market
- 9.4.1. UK Primary Sclerosing Cholangitis Market
  - 9.4.1.1. Type breakdown size & forecasts, 2025-2035
  - 9.4.1.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.4.1.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.4.1.4. End User breakdown size & forecasts, 2025-2035
- 9.4.2. Germany Primary Sclerosing Cholangitis Market
  - 9.4.2.1. Type breakdown size & forecasts, 2025-2035
  - 9.4.2.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.4.2.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.4.2.4. End User breakdown size & forecasts, 2025-2035
- 9.4.3. France Primary Sclerosing Cholangitis Market
  - 9.4.3.1. Type breakdown size & forecasts, 2025-2035
  - 9.4.3.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.4.3.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.4.3.4. End User breakdown size & forecasts, 2025-2035
- 9.4.4. Spain Primary Sclerosing Cholangitis Market
  - 9.4.4.1. Type breakdown size & forecasts, 2025-2035
  - 9.4.4.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.4.4.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.4.4.4. End User breakdown size & forecasts, 2025-2035
- 9.4.5. Italy Primary Sclerosing Cholangitis Market
  - 9.4.5.1. Type breakdown size & forecasts, 2025-2035
  - 9.4.5.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.4.5.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.4.5.4. End User breakdown size & forecasts, 2025-2035
- 9.4.6. Rest of Europe Primary Sclerosing Cholangitis Market
  - 9.4.6.1. Type breakdown size & forecasts, 2025-2035
  - 9.4.6.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.4.6.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.4.6.4. End User breakdown size & forecasts, 2025-2035
9.5. Asia Pacific Primary Sclerosing Cholangitis Market
- 9.5.1. China Primary Sclerosing Cholangitis Market
  - 9.5.1.1. Type breakdown size & forecasts, 2025-2035
  - 9.5.1.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.5.1.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.5.1.4. End User breakdown size & forecasts, 2025-2035
- 9.5.2. India Primary Sclerosing Cholangitis Market
  - 9.5.2.1. Type breakdown size & forecasts, 2025-2035
  - 9.5.2.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.5.2.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.5.2.4. End User breakdown size & forecasts, 2025-2035
- 9.5.3. Japan Primary Sclerosing Cholangitis Market
  - 9.5.3.1. Type breakdown size & forecasts, 2025-2035
  - 9.5.3.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.5.3.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.5.3.4. End User breakdown size & forecasts, 2025-2035
- 9.5.4. Australia Primary Sclerosing Cholangitis Market
  - 9.5.4.1. Type breakdown size & forecasts, 2025-2035
  - 9.5.4.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.5.4.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.5.4.4. End User breakdown size & forecasts, 2025-2035
- 9.5.5. South Korea Primary Sclerosing Cholangitis Market
  - 9.5.5.1. Type breakdown size & forecasts, 2025-2035
  - 9.5.5.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.5.5.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.5.5.4. End User breakdown size & forecasts, 2025-2035
- 9.5.6. Rest of APAC Primary Sclerosing Cholangitis Market
  - 9.5.6.1. Type breakdown size & forecasts, 2025-2035
  - 9.5.6.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.5.6.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.5.6.4. End User breakdown size & forecasts, 2025-2035
9.6. Latin America Primary Sclerosing Cholangitis Market
- 9.6.1. Brazil Primary Sclerosing Cholangitis Market
  - 9.6.1.1. Type breakdown size & forecasts, 2025-2035
  - 9.6.1.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.6.1.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.6.1.4. End User breakdown size & forecasts, 2025-2035
- 9.6.2. Mexico Primary Sclerosing Cholangitis Market
  - 9.6.2.1. Type breakdown size & forecasts, 2025-2035
  - 9.6.2.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.6.2.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.6.2.4. End User breakdown size & forecasts, 2025-2035
9.7. Middle East and Africa Primary Sclerosing Cholangitis Market
- 9.7.1. UAE Primary Sclerosing Cholangitis Market
  - 9.7.1.1. Type breakdown size & forecasts, 2025-2035
  - 9.7.1.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.7.1.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.7.1.4. End User breakdown size & forecasts, 2025-2035
- 9.7.2. Saudi Arabia (KSA) Primary Sclerosing Cholangitis Market
  - 9.7.2.1. Type breakdown size & forecasts, 2025-2035
  - 9.7.2.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.7.2.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.7.2.4. End User breakdown size & forecasts, 2025-2035
- 9.7.3. South Africa Primary Sclerosing Cholangitis Market
  - 9.7.3.1. Type breakdown size & forecasts, 2025-2035
  - 9.7.3.2. Treatment Type breakdown size & forecasts, 2025-2035
  - 9.7.3.3. Symptom Controls breakdown size & forecasts, 2025-2035
  - 9.7.3.4. End User breakdown size & forecasts, 2025-2035

Chapter 10. Competitive Intelligence

10.1. Top Market Strategies
10.2. Gilead Sciences, Inc.
- 10.2.1. Company Overview
- 10.2.2. Key Executives
- 10.2.3. Company Snapshot
- 10.2.4. Financial Performance (Subject to Data Availability)
- 10.2.5. Product/Services Port
- 10.2.6. Recent Development
- 10.2.7. Market Strategies
- 10.2.8. SWOT Analysis
10.3. Intercept Pharmaceuticals, Inc.
10.4. AbbVie Inc.
10.5. Bristol-Myers Squibb Company
10.6. Novartis AG
10.7. Pfizer Inc.
10.8. Takeda Pharmaceutical Company Limited
10.9. Roche Holding AG
10.10. Sanofi S.A.
10.11. Johnson & Johnson Services, Inc.
10.12. Merck & Co., Inc.
10.13. Amgen Inc.
10.14. Ipsen Pharma
10.15. Mitsubishi Tanabe Pharma Corporation
10.16. AstraZeneca PLC